Gef gene therapy enhances the therapeutic efficacy of doxorubicin to combat growth of MCF-7 breast cancer cells

Prados, José; Melguizo, Consolación; Rama, Ana R.; Ortíz, Raúl; Segura, Ana; Boulaiz, Houría; Vélez, Celia; Caba, Octavio; Ramos, Juan L.; Aránega, Antonia

doi:10.1007/s00280-009-1135-1

Cited by 20 publications

(12 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ultrathin sections were stained with uranyl acetate and lead citrate, and then analyzed by optical and transmission electronic microscopy (Hitachi H7000 transmission electron microscope, Tokyo, Japan). 24 Tumor induction and treatment Female C57BL/6 mice (Scientific Instrumentation Center, University of Granada) were used in the in vivo study. All mice (body weight: 25-30 g) were maintained in a laminar airflow cabinet placed in a room maintained at 37.0°C±0.5°C and 40%-70% relative humidity, with a 12-hour light/dark cycle under specific pathogen-free conditions.…”

Section: Transmission Electron Microscopymentioning

confidence: 99%

Enhanced antitumor activity of doxorubicin in breast cancer through the use of poly(butylcyanoacrylate) nanoparticles

Cabeza¹,

Ortíz²,

Arias³

et al. 2015

IJN

Self Cite

View full text Add to dashboard Cite

The use of doxorubicin (DOX), one of the most effective antitumor molecules in the treatment of metastatic breast cancer, is limited by its low tumor selectivity and its severe side effects. Colloidal carriers based on biodegradable poly(butylcyanoacrylate) nanoparticles (PBCA NPs) may enhance DOX antitumor activity against breast cancer cells, thus allowing a reduction of the effective dose required for antitumor activity and consequently the level of associated toxicity. DOX loading onto PBCA NPs was investigated in this work via both drug entrapment and surface adsorption. Cytotoxicity assays with DOX-loaded NPs were performed in vitro using breast tumor cell lines (MCF-7 human and E0771 mouse cancer cells), and in vivo evaluating antitumor activity in immunocompetent C57BL/6 mice. The entrapment method yielded greater drug loading values and a controlled drug release profile. Neither in vitro nor in vivo cytotoxicity was observed for blank NPs. The 50% inhibitory concentration (IC 50 ) of DOX-loaded PBCA NPs was significantly lower for MCF-7 and E0771 cancer cells (4 and 15 times, respectively) compared with free DOX. Furthermore, DOX-loaded PBCA NPs produced a tumor growth inhibition that was 40% greater than that observed with free DOX, thus reducing DOX toxicity during treatment. These results suggest that DOX-loaded PBCA NPs have great potential for improving the efficacy of DOX therapy against advanced breast cancers.

show abstract

Section: Transmission Electron Microscopymentioning

confidence: 99%

Enhanced antitumor activity of doxorubicin in breast cancer through the use of poly(butylcyanoacrylate) nanoparticles

Cabeza¹,

Ortíz²,

Arias³

et al. 2015

IJN

Self Cite

View full text Add to dashboard Cite

show abstract

“…Positive results of these strategies have been reported in bladder, pancreas and breast cancer (6)(7)(8). In lung cancer, the telomerase-specific oncolytic adenovirus combined with Gem resulted in a synergistic cytotoxic effect (9).…”

Section: Introductionmentioning

confidence: 96%

E phage gene transfection enhances sensitivity of lung and colon cancer cells to chemotherapeutic agents

Prados¹

2010

Int J Oncol

View full text Add to dashboard Cite

Abstract. The E gene from ºX174 encodes a membrane protein with a toxic domain that leads to a decrease in the tumour cell growth rate. With the aim of improving the antitumour effect on lung and colon cancer cells of the currently used chemotherapeutic drugs such as gemcitabine, carboplatin and paclitaxel, and 5-fluorouracil (5FU) plus folinic acid (FA) with irinotecan or oxaliplatine, we investigated a new combined therapy using these drugs associated to the transfection of E gene. Our results showed that E gene was able to decrease proliferation rate in A-549 and T-84 cells by inducing apoptotic the mitochondrial pathway. Significantly greater inhibition of proliferation was obtained using drugs in combination with E gene in comparison to single-agent treatments or controls. E gene combined with paclitaxel had the greatest effect on A-549 cells and combined with 5FU/FA/oxaliplatin on T-84 cells. Antitumour mechanisms of the chemotherapeutic drugs were enhanced by E gene, which itself has direct oncolytic effects inducing A-549 and T-84 apoptosis. Our in vitro results indicate that the combined therapy of E gene and cytotoxic drugs may be of potential therapeutic value as a new strategy for patients with advanced lung and colon cancer.

show abstract

“…In this context, gene therapy tries to modify or destroy the tumor cell uniquely from within, without causing damage to any other tissues. Recent studies have investigated several aspects of gene therapy related to cancer treatment; one of these approaches is suicide gene therapy [ 3 ], which may enhance the potential of the drugs typically used to treat cancer [ 4 ], including colon cancer [ 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

Specific Colon Cancer Cell Cytotoxicity Induced by Bacteriophage E Gene Expression under Transcriptional Control of Carcinoembryonic Antigen Promoter

Rama

Hernández

Perazzoli

et al. 2015

IJMS

Self Cite

View full text Add to dashboard Cite

Colorectal cancer is one of the most prevalent cancers in the world. Patients in advanced stages often develop metastases that require chemotherapy and usually show a poor response, have a low survival rate and develop considerable toxicity with adverse symptoms. Gene therapy may act as an adjuvant therapy in attempts to destroy the tumor without affecting normal host tissue. The bacteriophage E gene has demonstrated significant antitumor activity in several cancers, but without any tumor-specific activity. The use of tumor-specific promoters may help to direct the expression of therapeutic genes so they act against specific cancer cells. We used the carcinoembryonic antigen promoter (CEA) to direct E gene expression (pCEA-E) towards colon cancer cells. pCEA-E induced a high cell growth inhibition of human HTC-116 colon adenocarcinoma and mouse MC-38 colon cancer cells in comparison to normal human CCD18co colon cells, which have practically undetectable levels of CEA. In addition, in vivo analyses of mice bearing tumors induced using MC-38 cells showed a significant decrease in tumor volume after pCEA-E treatment and a low level of Ki-67 in relation to untreated tumors. These results suggest that the CEA promoter is an excellent candidate for directing E gene expression specifically toward colon cancer cells.

show abstract

Gef gene therapy enhances the therapeutic efficacy of doxorubicin to combat growth of MCF-7 breast cancer cells

Cited by 20 publications

References 39 publications

Enhanced antitumor activity of doxorubicin in breast cancer through the use of poly(butylcyanoacrylate) nanoparticles

Enhanced antitumor activity of doxorubicin in breast cancer through the use of poly(butylcyanoacrylate) nanoparticles

E phage gene transfection enhances sensitivity of lung and colon cancer cells to chemotherapeutic agents

Specific Colon Cancer Cell Cytotoxicity Induced by Bacteriophage E Gene Expression under Transcriptional Control of Carcinoembryonic Antigen Promoter

Contact Info

Product

Resources

About